5

15

20

## What is claimed is:

- An isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the TR6 polypeptide of SEQ ID NO:2 over its entire length; or a nucleotide sequence complementary to said nucleotide sequence.
  - 2. The polynucleotide of claim 1 which is DNA or RNA.
- The polynucleotide of claim 1 wherein said nucleotide sequence is at least 80% identical to that contained in SEQ ID NO:1.
  - 4. The polynucleotide of claim 3 wherein said nucleotide sequence comprises the TR6 polypeptide encoding sequence contained in SEQ ID NO:1.
    - 5. The polynucleotide of claim 3 which is polynucleotide of SEQ ID NO: 1.
  - 6. A DNA or RNA molecule comprising an expression system, wherein said expression system is capable of producing a TR6 polypeptide comprising an amino acid sequence, which has at least 80% identity with the polypeptide of SEQ ID NO:2 when said expression system is present in a compatible host cell.
    - 7. A host cell comprising the expression system of claim 6.
- 8. A process for producing a TR6 polypeptide comprising culturing a host of claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.

10

15

20

25

- 9. A process for producing a cell which produces a TR6 polypeptide thereof comprising transforming or transfecting a host cell with the expression system of claim 6 such that the host cell, under appropriate culture conditions, produces a TR6 polypeptide.
- 5 10. A TR6 polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO:2 over its entire length.
  - 11. The polypeptide of claim 10 which comprises the amino acid sequence of SEQ ID NO:2.
    - 12. An antibody immunospecific for the TR6 polypeptide of claim 10.
  - 13. A method for the treatment of a subject in need of enhanced activity or expression of TR6 polypeptide of claim 10 comprising:
  - (a) administering to the subject a therapeutically effective amount of an agonist to said receptor; and/or
  - (b) providing to the subject an isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the TR6 polypeptide of SEQ ID NO:2 over its entire length; or a nucleotide sequence complementary to said nucleotide sequence in a form so as to effect production of said polypeptide activity *in vivo*.
  - 14. A method for the treatment of a subject having need to inhibit activity or expression of TR6 polypeptide of claim 10 comprising:
  - (a) administering to the subject a therapeutically effective amount of an antagonist to said receptor; and/or
  - (b) administering to the subject a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said receptor; and/or
  - (c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said receptor for its ligand.

5

15

20

- 15. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of TR6 polypeptide of claim 10 in a subject comprising:
- (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said TR6 polypeptide in the genome of said subject; and/or
- (b) analyzing for the presence or amount of the TR6 polypeptide expression in a sample derived from said subject.
- 16. A method for identifying agonists to TR6 polypeptide of claim 10 comprising:
  - (a) contacting a cell which produces a TR6 polypeptide with a candidate compound; and
    - (b) determining whether the candidate compound effects a signal generated by activation of the TR6 polypeptide.
    - 17. An agonist identified by the method of claim 16.
  - 18. The method for identifying antagonists to TR6 polypeptide of claim 10 comprising:
  - (a) contacting said a cell which produces a TR6 polypeptide with an agonist; and
  - (b) determining whether the signal generated by said agonist is diminished in the presence of a candidate compound.
- 25 19. An antagonist identified by the method of claim 18.